Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab

Henit Yanai, Lev Lichtenstein, Amit Assa, Yoav Mazor, Batia Weiss, Arie Levine, Yulia Ron, Uri Kopylov, Yoram Bujanover, Yoram Rosenbach, Bella Ungar, Rami Eliakim, Yehuda Chowers, Raanan Shamir, Gerald Fraser, Iris Dotan, Shomron Ben-Horin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background & Aims: There is controversy about whether levels of anti-tumor necrosis factor (TNF) and antidrug antibodies (ADAs) are accurate determinants of loss of response to therapy. We analyzed the association between trough levels of anti-TNF agents or ADAs and outcomes of interventions for patients with loss of response to infliximab or adalimumab. Methods: We performed a retrospective study of pediatric and adult patients with inflammatory bowel disease and suspected loss of response to anti-TNF agents treated at medical centers throughout Israel from October 2009 through February 2013. We examined the correlation between outcomes of different interventions and trough levels of drug or ADAs during loss of response. An additional subanalysis was performed including only patients with a definite inflammatory loss of response (clinical worsening associated with increased levels of C-reactive protein or fecal calprotectin, or detection of inflammation by endoscopy, fistula discharge, or imaging studies). Results: Among 247 patients (42 with ulcerative colitis), there were 330 loss-of-response events (188 to infliximab and 142 to adalimumab). Trough levels of adalimumab greater than 4.5 mcg/mL and infliximab greater than 3.8 mcg/mL identified patients who failed to respond to an increase in drug dosage or a switch to another anti-TNF agent with 90% specificity; these were set as adequate trough levels. Adequate trough levels identified patients who responded to expectant management or out-of-class interventions with more than 75% specificity. Levels of antibodies against adalimumab >4 microgram per mL equivalent (mcg/mL-eq) or antibodies against infliximab >9 mcg/mL-eq identified patients who did not respond to an increased drug dosage with 90% specificity. Patients with high titers of ADAs had longer durations of response when anti-TNF agents were switched than when dosage was increased (P= .03; log-rank test), although dosage increases were more effective for patients with no or low titers of ADAs (P = .02). An analysis of definite inflammatory loss-of-response events (n= 244) produced similar results; patients with adequate trough levels had a longer duration of response when they switched to a different class of agent than when anti-TNF was optimized by either a dosage increase or by a switch within the anti-TNF class (P= .002; log-rank test). Conclusions: The results of this retrospective analysis suggest that trough levels of drug or ADAs may guide therapeutic decisions for more than two-thirds of inflammatory bowel disease patients with either clinically suspected or definite inflammatory loss of response to therapy.

Original languageEnglish
Pages (from-to)522-530.e2
JournalClinical Gastroenterology and Hepatology
Issue number3
StatePublished - 1 Mar 2015


FundersFunder number
Sheba Medical Center


    • Anti-TNF antibodies
    • Crohn's disease
    • IBD
    • UC


    Dive into the research topics of 'Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab'. Together they form a unique fingerprint.

    Cite this